A5000165494- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- FOXO transcription factor regulation
- Brain Metastases and Treatment
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Pituitary Gland Disorders and Treatments
- Radiation Therapy and Dosimetry
- Radiopharmaceutical Chemistry and Applications
- Urologic and reproductive health conditions
- Xenotransplantation and immune response
- Head and Neck Surgical Oncology
- Radiation Dose and Imaging
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research
Georgetown University
2019-2025
MedStar Georgetown University Hospital
2021-2025
Tampa General Hospital
2025
North Carolina Central University
2025
University of Florida
2025
Rush University Medical Center
2017-2018
Studies have demonstrated that injectable GnRH receptor agonists further suppress cancer progression when paired with radiotherapy (RT) in patients intermediate- to high-risk prostate adenocarcinoma. Relugolix is a newly available oral antagonist achieves swift and profound castration (total testosterone <20 ng/dl) at high rates, which may shape patients' health-related quality of life. The main objective this prospective study was explore the effects neoadjuvant relugolix on life...
Purpose: 18F-fluciclovine is a radiolabeled amino acid analog that preferentially taken up by prostate cancer cells. PET/CT scans are approved for the detection of biochemically recurrent cancer. Stereotactic body radiation therapy (SBRT) increasingly offered treatment localized Limited data exist on patterns failure following SBRT. The impact scan timing before or after meeting Phoenix criteria unknown. Here, we characterize 18F-fluciclovine-defined recurrences patients with rising...
Purpose Intensity-modulated radiation therapy (IMRT) with brachytherapy boost for unfavorable prostate cancer has been shown to improve biochemical relapse-free survival compared IMRT alone. Stereotactic body (SBRT) is a less-invasive alternative brachytherapy. Early outcomes utilizing SBRT suggest low rates of high-grade toxicity maintained patient-reported quality life. Here, we report the 5-year progression-free (PFS) and cancer-specific (PCSS) patients treated plus boost. Materials...
In patients with localized prostate cancer, 5-fraction, stereotactic body radiation therapy (SBRT) has been found to offer comparable oncologic outcomes and potential for improved treatment compliance compared conventional, 40-plus fraction (RT). Recent studies of patient experiences have highlighted both the impact therapy-associated financial toxicity (FT) on adherence health-related quality life (HRQOL).A cross-sectional assessment FT after SBRT was performed using 12-item COST...
Stereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of visits from over 40 five may ease burden increase accessibility logistically challenged patients. Travel distance is one factor that affects a patient's access often related geographic location socioeconomic status. In this study, we review demographic factors patients treated SBRT...
Prostate cancer is the most frequently diagnosed solid malignancy in men. African American (AA) men are at greater risk for developing prostate cancer, and experience higher mortality rates, as compared with Caucasian However, mechanistic studies to understand this health disparity have been limited by lack of relevant vitro vivo models. There an urgent need preclinical cellular models investigate molecular mechanisms underlying AA We collected clinical specimens from radical prostatectomies...
Clinical trials of anti-Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated (CTLA-4) therapies have demonstrated a clinical benefit with low rates neurologic adverse events in patients melanoma brain metastases (MBMs). While the combined effect these immunotherapies (ITs) stereotactic radiosurgery (SRS) has yielded impressive results regard to local control (LC) overall survival (OS), it also been associated increased radiation necrosis (RN) compared historical...
Purpose: Retaining quality of life in patients treated with SBRT for prostate cancer remains paramount. As such, balancing the benefits treatment against effects therapy on elderly is essential. The EORTC QLQ-ELD14 (ELD-14) a validated questionnaire domain dedicated to burden illness and elderly. Expanded Prostate Cancer Index Composite (EPIC)-26 which measures urinary, bowel, sexual, hormonal symptoms. This study reports trends self-reported reveals convergence related side obtained from...
117 Background: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy (RT) for unfavorable intermediate- high-risk prostate cancer. Relugolix is a new oral antagonist that achieves high rates of rapid profound castration (total testosterone < 20 ng/dL), which may impact health-related quality life. This prospective study sought evaluate the neoadjuvant relugolix on life in patients prior start RT. Methods: Patients treated at...
319 Background: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy (RT). Relugolix is an oral antagonist that achieves rapid testosterone suppression. Non-adherence medications due poor social support or bothersome side effects may increase the risk of recurrence. This prospective study sought evaluate early suppression and relugolix drug adherence RT. Utilization patient-reported outcomes (PROs) medication guide intervention...
Purpose/Objectives ZAP-X, a novel and dedicated radiosurgery (SRS) system, has recently emerged, while CyberKnife solidified its position as versatile solution for SRS stereotactic body radiation therapy over the past two decades. This study aims to compare dosimetric performance delivery efficiency of ZAP-X in treating brain metastases varying target sizes, employing circular collimation. Methods materials Twenty-three patients, encompassing total 47 metastases, were included creation...
Following treatment for localized prostate cancer, a subset of men will develop recurrent disease in the abdominopelvic nodes. For radiation therapy (RT), optimal volume, fractionation schedule, and dose remain unanswered questions. We report early outcomes patients treated with involved-field stereotactic body (SBRT) (IF-SBRT) nodal oligo-recurrent (NOR) cancer.
Introduction SBRT is an increasingly popular treatment for localized prostate cancer, though considerable variation in technical approach common and optimal dose constraints are uncertain. In this study, we sought to identify dosimetric patient-related predictors of acute rectal toxicity.
<div><p>Prostate cancer is the most frequently diagnosed solid malignancy in men. African American (AA) men are at greater risk for developing prostate cancer, and experience higher mortality rates, as compared with Caucasian However, mechanistic studies to understand this health disparity have been limited by lack of relevant <i>in vitro</i> vivo</i> models. There an urgent need preclinical cellular models investigate molecular mechanisms underlying AA We...
<p>Figure S3: Immunocytochemistry analysis of normal (N) and tumor (T)- derived paired cell cultures AP4 AP10. Normal cells from AP10 were stained with indicated antibodies. DAPI (bottom in blue) the nucleus. CK8, HMW CK, TOPK mainly located cytoplasm.</p>